FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Baruch D. Kuppermann, MD, PhD, shares positive data on the dexamethasone intravitreal implant for diabetic macular edema.
The retrospective analysis included 167 patients with a suboptimal response to anti-VEGF treatment.
“We either continued them on standard-of-care anti-VEGF injections or DEX implant was initiated,” he said. “The evaluation was of how they did over a 12-week period after that initial treatment with DEX implant vs. continuing standard of care with anti-VEGF therapy.”